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Since its proposal in 1994, the amyloid cascade hypothesis has prevailed as the mainstream research subject on the molecular
mechanisms leading to the Alzheimer’s disease (AD). Most of the ﬁeld had been historically based on the role of the diﬀerent
forms of aggregation of β-amyloid peptide (Aβ). However, a soluble intracellular fragment termed amyloid precursor protein
(APP) intracellular domain (AICD) is produced in conjunction with Aβ fragments. This peptide had been shown to be highly
toxic in both culture neurons and transgenic mice models. With the advent of this new toxic fragment, the centerpiece for the
ethiology of the disease may be changed. This paper discusses the potential role of multiprotein complexes between the AICD and
its adapter protein Fe65 and how this could be a potentially important new agent in the neurodegeneration observed in the AD.
1.Introduction
The APP is a type I transmembrane protein with characteris-
tics of an orphan receptor, which shares with other members
ofitsclassaparticularsignalingmechanismtermedregulated
intramembrane proteolysis (RIP) [1].
RIP requires that the transmembrane protein undergoes
two consecutive cleavage events. The ﬁrst occurs outside the
transmembrane domain, usually in response to ligand bind-
ing, inducing the release of the extracellular domain. This
ﬁrst cleavage event elicits a conformational change that trig-
gers the second proteolytic cleavage which takes place on
the transmembrane segment. The intracellular cytoplasmic
fragment released translocates to the nucleus where it acti-
vatesgenetranscription[1].Thismechanismcontrolsseveral
cellular processes, such as the unfolded protein response [2],
cholesterol synthesis [3], and cell fate instruction [4].
RIP of the APP is mediated by three diﬀerent proteases.
While α-a n dβ-secretases catalyze extracellular cleavage, the
γ-secretase complex cuts at the intramembrane domain and
leads to the generation of two peptides: an APP active frag-
ment, termed AICD and the Aβ [1]. The stoichiometry of
both AICD and Aβ fragments has been a controversial issue.
One study shows that the absence of the β-secretase does not
aﬀect AICD production [5]. In contrast, two independent
groups indicate that AICD is produced mainly from the 695
aminoacidsisoformofAPPthroughtheamyloidogenicpath-
way (dependent on β-secretase activity) [6, 7] and is there-
fore generated in equimolar quantities with Aβ [8]. The last
one accumulation and the formation of various aggregates
and deposits in the brain have been the main hypothesis
to explain the neuropathological development of AD for
almost 20 years [9]. Initially, the study of the functions
associated with the AICD was limited by the hindrance in
its detection [10]. However, recent studies showing that the
levels of the AICD are increased in brains of AD patients and
murine models reproducing the disease [11], open up the
possibility that this fragment participates in the molecular
mechanisms contributing to AD.2 International Journal of Alzheimer’s Disease
2. The AICD Interactome: Functionsand
Dysfunctionsinthe Routeto AD
The AICD is the most evolutionarily-conserved region of the
APP, accounting for its functional importance. Despite its
relatively small size (59 aminoacids or less), it acts as a dock-
ingsiteforaparticularlylargegroupofintracellularproteins.
Amongst this group of proteins are Pin1 [12], the X11 pro-
tein family [13], disabled (Dab)-1 [14], Shc [15], JNK-inter-
acting protein (JIP)-1 [16], and the Fe65 protein family
[17–19], which includes Fe65 itself and two closely related
homologues, Fe65L1 and Fe65L2. Fe65 family members con-
tain three protein-protein interaction domains: a WW do-
mainattheN-terminalinvolvedininteractionswithproline-
rich sequences and two phosphotyrosine binding domains
(PTB1andPTB2)locatedattheC-terminal.ThesecondPTB
domain (PTB2) is responsible for the interaction between
Fe65 and the sequence 682YENPTY687 of the APP (follow-
ing the numbering of the APP695 isoform). The interaction
between these proteins occurs in a Tyr682 phosphorylation-
independent manner [13]. The possibility of AICD to form
multiprotein complexes through its association with Fe65
anditsmultipleligands(Table 1) has unexpectedly expanded
the potential roles of AICD.
2.1. Roles in APP Traﬃcking and Processing. AICD binds to
Fe65 in a region that is essential for Aβ production, making
Fe65 a good candidate for regulating APP processing. This
could occur via two mutually-exclusive pathways: the amyl-
oidogenic pathway, leading to Aβ production mediated by
the β-secretase and the nonamyloidogenic pathway leading
to the production of a large extracellular fragment (sAPPα),
which is mediated by the α-secretase and prevents the gen-
eration of Aβ. Fe65 acts as a potent modulator by altering
thebalancebetweenthetwopathways.Theoverexpressionof
Fe65 in cell lines induces a dramatic increase in Aβ secretion
[40],whereasAβsecretionwasdecreasedinFe65knockdown
cells [41] and in hippocampal neurons of Fe65/Fe65L1
knockout (KO) mice [42]. The eﬀect on the Aβ secretion
appearstobedependentontheinteractionbetweenFe65and
APP, because the knock-in mice carrying the Y682G muta-
tion,thatinhibitsAICDbindingtoFe65,showdecreasedlev-
els of Aβ and a massive increase in sAPPα, as a consequence
of the nonamyloidogenic pathway [43]. This is in agreement
with a study showing that Fe65 is a potent suppressor of the
nonamyloidogenic pathway in primate cells [44].
The mechanism by which Fe65 modulates Aβ secretion
is related to its interaction with the apolipoprotein E (ApoE)
receptors: the low density lipoprotein receptor-related pro-
tein (LRP) [22] and ApoE receptor 2 (ApoER2) [30].
Related to the participation of the aforementioned
receptors, the eﬀect of Fe65 in the secretion of soluble APP
fragments is lost in cells lacking LRP [45]. The functional
relation with ApoER2 is more complex and depends on the
presenceofitsextracellularligand,reelin,anditsintracellular
adapter, Dab-1. Reelin reduces Aβ secretion by promoting
the binding of Dab1 to the APP and displacing Fe65, because
they share the same binding region [46]. A decrease in
Table 1: Fe65 interactors and its functions.
Protein Domain
involved
Putative functions of
the interaction
References
Amyloid
precursor protein
(APP)
PTB2
Regulation of Aβ
secretion, nuclear
signaling, and
cytoskeleton regulation
[17]
Mammalian
enabled (Mena) WW Actin polimerization [20]
CP2/LSF/LBP1 PTB1
Transcriptional
regulation, GSK-3β
expression
[21]
Low-density
lipoprotein
receptor-related
protein (LRP1)
PTB1 APP traﬃcking, Aβ
secretion
[22]
Abl tyrosine
kinase WW Nuclear signaling [23]
Tat-interacting
protein 60kDa
(Tip60)
PTB1 Nuclear signaling,
DNA repair
[24]
Alcadein ND APP metabolism [25]
Nucleosome
assembly factor
SET
WW Transcriptional
regulation
[26]
Tau PTB1 Cytoskeleton
regulation
[27]
14-3-3γ
Between
WW and
PTB1
Nuclear signaling [28]
P2X receptor WW Synaptic transmission [29]
ApoER2 PTB1 APP traﬃcking, Aβ
secretion
[30]
Estrogen receptor
α ND Transcriptional
regulation
[31]
NIMA-related
kinase 6 WW Apoptosis [32]
Glycogen
synthase
kinase-3β
WW Kinase activation [33]
Dexras1 PTB2 Nuclear signaling [34]
Teashirt PTB1 Repression of caspase 4
expression
[35]
Neuronal
precursor cell
expressed
developmentally
down regulated
4-2 (Nedd 4-2)
WW Fe65 ubiquitylation [36]
Dab1 ND APP processing [37]
Megalin ND Axonal branching, APP
traﬃcking
[38]
Rac1 ND Fe65 expression [39]
ND: Not determined
Reelin expression in the entorhinal cortex (the ﬁrst region
of the brain where Aβ deposits can be observed), displayed
in PDAPP transgenic mice (which carry human APP withInternational Journal of Alzheimer’s Disease 3
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Figure 1: APP processing pathways involved in the activation and release of the AICD-associated complexes from the plasma membrane.
Fe65 is in an autoinhibited conformation in the cytoplasm. The binding to the AICD triggers the exposure of Fe65 WW and PTB1 domains.
These protein-protein domains elicit the recruitment to the subcortical domains of the plasma membrane of both c-Abl and Tip60. At
the plasma membrane, c-Abl can phosphorylate and activate the protein kinase CDK-5 at Tyr15, and in turn, activated CDK-5 may
phosphorylate Ser90 of Tip60. DNA damage or other unknown stimuli may then induce the release of the complex from the membrane
through two complementary mechanisms: either by the activation of the γ-secretase or by JNK-dependent phosphorylation of Thr668 in the
AICD. In spite of the preferred mechanisms involving the release of the Fe65-complex, it can be translocated to the nucleus where it activates
transcription of target genes and is essential in the repair of the DNA double strand-breaks (DSB).
mutations Swedish (swe) and Indiana) and in AD patients
[47], could seriously aﬀect the balance of Dab1 and Fe65 in
theirbindingtoAICD,increasingAβsecretion.Thishasbeen
observed in transgenic mice which lack Reelin expression
(reeler) and carry the mutations swedish and arctic in APP
[48].
2.2. Roles in Transcription. Ad e c a d ea g o ,ap o s s i b l er o l ef o r
theRIPofAPPwasﬁrstsuggested[24].SinceAPPprocessing
seemstobesimilartoNotchprocessing,ithasbeensuggested
that RIP of APP could be involved in transcriptional regu-
lation. In fact, the fusion of the DNA binding domain of
yeast Gal4 (Gal4DB) to the C-terminal of APP induced a
strong transactivation of a luciferase reporter dependent on
the formation of a trimeric complex with the adapter protein
Fe65 and the histone acetyltransferase Tip60 [24]. A recipro-
cal experiment using Tip60 or Fe65 fused to the Gal4DB gave
rise to some contradictory results [49, 50]. Nevertheless, a
consensus model can be generated including the vast major-
ity of observations derived from these studies (Figure 1).
(i) The APP acts as an anchor for Fe65 and Fe65-asso-
ciated proteins that is,: Tip60, inducing its associa-
tion with membrane compartments [51]. Membrane
recruitment seems to be essential for the activation
of the complex, since the overexpression of soluble
AICD has no eﬀect on transactivation [49].
(ii) ThebindingofAPPtoFe65inducesaconformational
change that “opens” the autoinhibited conformation
of Fe65, produced by the association of the WW
domain with a region ﬂanked by the PTB1 and PTB2
domains [49].
(iii) The association with the plasma membrane allows
the activation of the complex, induced by the phos-
phorylation of Tip60 by cyclin-dependent kinases
(CDKs) [52]. An excellent prospective candidate is
CDK-5, that can be found associated with plasma
membranes through its activator p35 and displays
high activity in the brain [53].
(iv) The release of the complex from the plasma mem-
brane may be produced by the APP cleavage by γ-
secretase [24] or additionally by the APP phosphory-
lationatThr668[54]whichinducesaconformational
change in the region recognized by Fe65, decreasing
the aﬃnity for each other [55].
(v) Although some groups have observed AICD in the
nucleus [56], particularly in nuclear domains such
as transcriptional factories [57], the splicing factor4 International Journal of Alzheimer’s Disease
compartment [58] or directly at promoters of some
genes [59–61], apparently in the artiﬁcial transacti-
vation system, the nuclear translocation of AICD is
not essential to enhance luciferase expression [49].
(vi) The N-terminal region of Fe65 that includes the WW
domain is necessary for nuclear translocation [51]
and therefore for its activity as a transactivating pro-
tein [24]. Although this region lacks a nuclear local-
ization sequence (NLS), it could be directed to the
nuclei by association with a protein carrying a func-
tional NLS. A good candidate to perform this func-
tion would be the nucleosome assembly protein SET
that binds the WW domain and is required for trans-
activation mediated by the Fe65Gal4DB fusion pro-
tein [26].
(vii) The phosphorylation of Tyr547 in the Fe65 PTB2
domain mediated by the Abl kinase stimulates its tra-
nsactivational activity [62], possibly preventing the
associationofFe65withDexras,aRasfamilyGTPase,
that acts as an inhibitor of the complex [34].
The search for target genes regulated by the AICD has
been complex and has yielded conﬂicting ﬁndings. It has
been reported that the AICD/Fe65 complex regulates the
APP expression itself [63], glycogen synthase kinase (GSK)-
3β [63, 64], Tip60 [63], the β-secretase (BACE1) [63], the
primate-speciﬁc caspase 4 [35], the Aβ degrading enzyme
neprylisin [61, 65, 66], the tetraspanin KAI1 [26, 63], the
lipoprotein receptor-related protein (LRP1) [60], the epi-
dermal growth factor receptor (EGFR) [67], and the tumor
suppressorp53[68].Nevertheless,manyofthesestudieshave
been refuted by others, which using diﬀerent strategies for
modulating the AICD/Fe65 complex did not produce chan-
ges in the expression of the aforementioned genes [69–73].
The possible origin of the reported diﬀerences is un-
clear, but regarding the most intensively discussed target, ne-
prilysin, recent data may shed light on the controversy. It was
shown that the AICD-binding to neprilysin gene promoter is
celltype-dependent[61,74].Furthermore,AICD-dependent
gene regulation is inﬂuenced by the passage number and cell
density [75], providing two likely experimental explanations
for this disagreement.
2.3. Roles in DNA Repair. The majority of the evidence
pointing to a role of AICD in transcriptional responses de-
rives from the use of artiﬁcial reporter systems that in fact
measure the release of components from the membrane,
without monitoring endogenous transcriptional activity. Be-
sides the potential participation of Fe65 in promoting the
expression of several genes described above, Fe65 has been
also proposed to perform other nuclear functions such as
the repair of DNA damage. Fe65 KO mice are more sensitive
to DNA damage, and this can be overcome by increasing
the availability of nuclear Fe65 [76]. Moreover, genotoxic
damageproducesarapidtranslocationofFe65tothenuclear
matrix [77] and stimulates APP processing by the γ-secretase
complex [76] and APP phosphorylation in Thr668 [77],
two mechanisms that allow translocation to the nucleus of
the complexes associated with AICD. Fe65 is required for
eﬃcient repair of DNA double strand breaks (DSB), a func-
tion that depends on its interaction with Tip60 and AICD
[78]. The Fe65-dependent recruitment of Tip60 to DSB
sites is essential because the histone acetyltransferase activity
leads to chromatin opening at the injury site, enabling the
access of the complexes involved in repair [79]. On the other
hand, Tip60 acetylates and activates the ataxia telangiectasia
mutated (ATM) kinase [80] which in turn phosphorylates
a histone H2A variant, called H2AX, which acts as a mark
for the recruitment of the reparation machinery. Changes
in H2AX phosphorylation could be also dependent on the
stability of p53 in a mechanism that requires the accu-
mulation of Fe65 in the nuclei [81, 82]. However, the fact
that phosphorylated H2AX may be also increased in Fe65
KO cells under genotoxic damage [76] suggests that com-
plementary mechanisms may regulate this behavior.
2.4. Roles in Brain Development. Fe65 is highly enriched in
the brain where it is expressed as two isoforms produced by
the alternative splicing of a 6 bp miniexon. The isoform that
includes this exon (which encodes Arg-Glu inserted in the
PTB1 domain) is expressed exclusively in neurons, whereas
theisoformlackingthesetwoaminoacidsisexpressedonlyin
nonneuronal cells [83]. Fe65 protein expression may change
during development [84] and also in pathological conditions
such as AD [85], opening up the possibility that it partic-
ipates in plastic processes in neurons, which is reﬂected in
the phenotype of Fe65 and Fe65L1 double KO mouse. These
mice exhibit defects in the positioning of cortical neurons
characterized by the presence of ectopic neurons that break
the pialmeningeal basement membrane and displace Cajal-
Retzius neurons and also have serious defects in axonal
projections [86]. Many of these phenotypical features are
shared by mice lacking some of the Fe65-binding partners
such as the APP family [87] and the mammalian homolog of
Drosophilaenabled(Mena)[88].Menabelongstoafamilyof
proteins that regulate actin dynamics and thereby modulate
cell motility and morphology. Mena is located in areas of
dynamic actin remodeling such as lamellipodia and growth
cones and interacts with the actin-binding protein, proﬁlin.
Mena interacts with the Fe65 WW domain, assembling
a macromolecular complex with APP [20] that regulates
axonal branching [89], cell motility [90], and possibly the
dynamics of actin at the growth cone and synapsis [91].
I nap r e v i o u sa t t e m p tt og e n e r a t eaF e 6 5K O ,i tw a s
expressedatruncatedproteinlackingtheN-terminaldomain
and translated from Met261. This 60kDa variant does
not contain the WW domain and does not display the
transactivation activity of the larger isoform [92]. In spite
of the expression of this smaller protein, the animal shows
defects in hippocampal-dependent learning and long-term
potentiation (LTP) [93, 94]. However, it is diﬃcult to assess
whether these defects are due to the 97kDa isoform loss or
the appearance of this new 60kDa isoform acting as a domi-
nant negative protein. Behavioral studies in Fe65/Fe65L1 KO
mice could help to clarify these points.International Journal of Alzheimer’s Disease 5
3. The AICD/Fe65 Transgenic Mice: New
PerspectivesinAD
Although the amyloid cascade hypothesis has become the
mainstream in the study of AD neurobiological mechanisms,
several groups have recently suggested that this should be at
least reevaluated in the light of new ﬁndings [95–97]. Trans-
genicmicethatoverexpresstheAICDandtheadapterFe65in
the forebrain (under the control of the CaMKIIα promoter)
[98] display several neuropathological features observed in
various transgenic models and in the AD patients brains,
with the exception that they do not show Aβ accumulation
in the brain [11]. The expression of AICD together with
Fe65 seems to be essential to induce an AD-like phenotype in
the transgenic model, since a single AICD transgenic mouse
developed by an independent group does not present the
characteristics of the double transgenic [99], indicating that
the functional relationship between both proteins, discussed
in the previous sections, is indeed essential.
3.1. Cell Signaling Alterations. As in the brain of patients
with AD and several other transgenic models used to study
AD, the AICD/Fe65 mice show an increase in GSK-3β ac-
tivity. Interestingly, the double AICD/Fe65 transgenic does
not aﬀect the GSK-3β mRNA or protein levels, as would be
expected from a previous study which suggests that the
kinase should be transcriptionally regulated by the AICD/
Fe65 complex [64]. Kinase activation in the double trans-
genicis indeed correlatedwith an increasein theTyr216 acti-
vating phosphorylation and a decrease in the Ser9 inhibitory
phosphorylation [98]. A molecular explanation for this may
be related with the fact that Fe65, through its WW domain,
interacts and promotes GSK-3β phosphorylation on Tyr216
[33]. Increased GSK-3β activity in the AICD/Fe65 mice
produces hyperphosphorylation of two direct targets: the
microtubule-binding proteins, collapsin-response mediator
protein (CRMP)-2 and tau [11, 98]. Increased CRMP-2
phosphorylation is also found in transgenic mice expressing
mutated forms of APP and presenilin (PS)-1 and also in the
cerebral cortex of AD patients. Increased CRMP-2 phos-
phorylation is an early event that precedes the formation
of amyloid plaques and neuroﬁbrillary tangles. Interestingly,
this posttranslational modiﬁcation seems to be speciﬁc for
AD, since it has not been reported in other neurodegenera-
tive conditions like the frontotemporal dementia and Pick’s
Disease [100, 101].
Hyperphosphorylation of tau is the initial event in the
pathway to tau self-aggregation, forming the paired helical
ﬁlaments (PHFs). PHFs are found at the core of the highly
insoluble intraneuronal neuroﬁbrillary tangles, one of the
two neuropathological lesions (another is the senile plaques)
that characterize the AD patients brains. The AICD/Fe65
mouse shares with 3xTg mice [102] the capacity to promote
the formation of tau insoluble aggregates, which are not ob-
served in most mouse models for AD [11].
3.2. Neuronal Activity Impairments. The AICD/Fe65 double
transgenic mouse has nonconvulsive seizures with aging,
abnormal electroencephalogram (EEG) spiking, and a
greater sensitivity to seizures induced by kainic acid (KA)
in young animals [103]. It also presents several alterations
in hippocampal neural circuits, characterized by abnormal
sprouting of the mossy ﬁber terminals with increased
neuropeptide Y (NPY) expression and loss of calbindin-
positive neurons [104]. Alterations in the EEGs and seizures
have been observed in AD patients and in mouse models for
this pathology, such as mice R1.40 (with APPswe), APPPS1,
and PDAPP [105, 106].
3.3. Memory Deﬁcits and Neurodegeneration. Aged AICD/
Fe65 animals (>18 months) show neurodegeneration in the
CA3 hippocampal area, although the defects in working
memory (evaluated by the Y maze paradigm) start at a
young age (8 months). Interestingly, these changes occur in
the absence of increased Aβ levels [11]. Since most of the
mouse models for AD are based on the expression of mu-
tant variants of the human APP or presenilin found in cases
of familiar AD, the identity of neurotoxic APP fragments
has not been clearly discerned yet. Several studies have
shown that Aβ deposition in senile plaques does not corre-
late with neuronal death and cognitive deﬁcits present in
diﬀerent transgenic models [107, 108]. For example, the
overexpression of wild type hAPP in mice produces memory
deﬁcits, tau hyperphosphorylation, synaptic loss, and neu-
rodegeneration without inducing an increase in Aβ levels
[109]. Surprisingly, overexpression of hAPP together with β-
secretase in mice induces a decrease in Aβ levels and plaque
deposition, but the animals suﬀer severe neurodegenerative
disorders and learning defects [110]. In both models, an
accumulation of C-terminal fragments of APP including the
AICD is observed [109, 110]. Is it therefore possible that this
fragmentgeneratedalongwiththeAβ mayberesponsiblefor
the alterations in transgenic models of AD? Interestingly, the
AD model termed PDAPP, when combined with a mutated
form of the AICD (D664A), shows a complete reversion of
the neuropathological hallmarks of the disease, including
synaptic loss, the dentate gyrus atrophy, the astrogliosis,
the deﬁcits in synaptic transmission and memory, and the
behavioral abnormalities without aﬀecting the Aβ levels or
the plaque accumulation [111–114]. These results strongly
suggest that the causal relationship between the Aβ accumu-
lation and the neuropathological defects usually associated
with AD may be challenged and position the AICD as a
good candidate to explain the eﬀects observed in various
transgenic models based on mutations in APP and PS1.
4. Conclusions
ThetwohallmarksofAD,theamyloidplaques,andneuroﬁb-
rillary tangles, which are elegantly related through the amy-
loidcascadehypothesis, arethemaincomponentsin thecur-
rent research on the molecular mechanisms leading to this
pathology. Since its origin, the amyloid cascade hypothesis
has accumulated substantial evidence in its support, which
has virtually overshadowed the fact that clinical trials based
onthishypothesis havebeen showntobeunsuccessful[115].6 International Journal of Alzheimer’s Disease
One of many possibilities to explain the failure of clinical
trialscouldberelatedwiththefactthatseveralmousemodels
express the human-mutated APP found in familial AD, so
it is unclear which abnormalities detected in these models
are product of speciﬁc Aβ species (like oligomers) or another
toxic metabolites of APP (like AICD) or simply due to eﬀects
of overexpression of hAPP. However, the evidence collected
from the transgenic models here reviewed could help to dis-
cernwhethertheAβspeciesortheAICDarethekeyelements
triggering neurodegeneration. Three independent transgenic
mice lines (a single transgenic of hAPP, a double AICD/Fe65
transgenic, and the double hAPP/β-secretase transgenic)
recapitulate the neuropathological alterations of the disease
withoutanyincreaseinAβsecretion.Allofthesemodelshave
an accumulation of the APP C-terminal fragments. More-
over, the introduction of a point mutation in the AICD in
transgenic mice expressing the hAPP with the swe and Indi-
ana mutations, the AD-like phenotype is reversed, in spite of
increased Aβ production. All of these evidences suggest that
the AICD could be acting as the bona ﬁde toxic intermediate
in the AD progression and could become a target for future
therapeutic interventions against this devastating disease.
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